Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study
| العنوان: | Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study |
|---|---|
| المؤلفون: | Miguel Lanaspa, Concepció Figueras, Pere Soler-Palacín, Eva María Roselló, Andrea Martín-Nalda, Leonor Pou, Cristina Diaz de Heredia, Marie Antoinette Frick |
| المصدر: | Journal of Antimicrobial Chemotherapy. 67:700-706 |
| بيانات النشر: | Oxford University Press (OUP), 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Male, Microbiology (medical), medicine.medical_specialty, Allergy, Antifungal Agents, Adolescent, Drug-Related Side Effects and Adverse Reactions, Immunocompromised Host, Plasma, Pharmacokinetics, Internal medicine, medicine, Humans, Pharmacology (medical), Prospective Studies, Child, Prospective cohort study, Adverse effect, Pharmacology, Voriconazole, business.industry, Incidence, Incidence (epidemiology), Infant, Cancer, Triazoles, medicine.disease, Pyrimidines, Treatment Outcome, Infectious Diseases, Mycoses, Child, Preschool, Anesthesia, Toxicity, Female, Drug Monitoring, business, medicine.drug |
| الوصف: | OBJECTIVES To evaluate voriconazole plasma level monitoring in immunocompromised children and determine the relationship of plasma levels with dose, safety and efficacy. METHODS We used a prospective study including all consecutive children with invasive fungal infection (IFI) treated with voriconazole between August 2008 and May 2010. IFI diagnosis and clinical outcome evaluation were based on European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group ('EORTC/MSG') definitions. RESULTS A total of 196 voriconazole plasma trough measurements from 30 patients (median age 10 years) obtained during 2135 days of voriconazole therapy were analysed. Nineteen patients (63%) presented with proven or probable IFI. Voriconazole plasma levels varied widely and 73% of patients required dose adjustment. The median voriconazole dose was 20 mg/kg/day and the median duration of therapy was 6 weeks. Age 5 was the smallest value defining two groups on which the correlation between dose and plasma levels had a different behaviour, and this relationship was especially significant for patients |
| تدمد: | 1460-2091 0305-7453 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c3cd45ce30da3add14c6194f6224baf https://doi.org/10.1093/jac/dkr517 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....6c3cd45ce30da3add14c6194f6224baf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14602091 03057453 |
|---|